Acetylcholine Inhibition
Acetylcholine Inhibition - Related Videos
06:39
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
0 Views •
Cited by 36 •
2016
Intracoronary acetylcholine testing has been established for the assessment of epicardial coronary spasm more than 30 years ago. Recently, the focus has shifted towards the microcirculation and it has been shown that microvascular spasm can be detected using ACH-testing. This article describes the ACH-test and its implementation in daily routine.
00:46
Feedback Inhibition
0 Views •
2019
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell! Since enzymes help control the rate of reactions, their activity is regulated so that appropriate amounts of starting materials, intermediate metabolites, and products are maintained in the cell. Excessive build-up or depletion of...
10:04
Local Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices
0 Views •
Cited by 23 •
2012
In this paper, we describe a useful method to study ligand-gated ion channel function in neurons of acutely isolated brain slices. This method involves the use of a drug-filled micropipette for local application of drugs to neurons recorded using standard patch clamp techniques.
07:59
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
0 Views •
Cited by 3 •
2022
This protocol presents the acetylcholine rechallenge after nitroglycerine as an add-on procedure to spasm provocation testing. The purpose of this technique is to unmask co-existing microvascular spasm in patients with epicardial spasm and to assess the protective efficacy of nitroglycerine on a per-patient level to guide medical therapy.
09:06
Localization of Plasma Membrane and Intracellular Neuronal Nicotinic Acetylcholine Receptors Using Quantitative Imaging in Mammalian Cells
0 Views •
2025
This protocol describes expression and quantification of neuronal nicotinic acetylcholine receptors subunits using the mammalian Neuro-2a cell line. pH-sensitive fluorescent tags and confocal microscopy enable precise evaluation of receptor localization at the plasma membrane versus those expressed in pH-neutral intracellular compartments, facilitating the study of nAChR trafficking and pharmacological modulation.
FAQs
Receptor blockade leaves acetylcholine present but prevents it from activating its target, whereas release inhibition lowers the neurotransmitter reaching the synapse. Muscarinic and nicotinic antagonists act at receptor sites, while botulinum toxin acts presynaptically. This distinction helps pharmacologists predict whether inhibition will be localized to a receptor class or reflect reduced transmission more broadly.
The affected receptor class determines which cholinergic functions are most directly altered. Muscarinic blockade is relevant to autonomic regulation, glandular secretion, airway tone, and cognition, while nicotinic blockade can influence signaling through autonomic ganglia or communication involved in skeletal muscle contraction. Identifying the subtype therefore connects a drug mechanism with its expected physiological effects.
Acetylcholine signaling operates in several systems, so inhibition produces outcomes that depend on the pathway being interrupted. Blocking muscarinic activity may change heart rate, airway tone, or secretion, whereas interfering with nicotinic signaling can affect autonomic transmission or muscle movement. The location and receptor type provide the mechanistic explanation for these differing responses.
These drug categories inhibit different components of cholinergic signaling. Antimuscarinic drugs block muscarinic receptors, ganglionic blockers interfere with nicotinic transmission in autonomic ganglia, and neuromuscular blockers affect nicotinic signaling associated with skeletal muscle movement. Comparing their targets helps distinguish effects on autonomic regulation from effects on muscle contraction.
A useful analysis begins by identifying whether the intervention blocks muscarinic receptors, blocks nicotinic receptors, or reduces presynaptic acetylcholine release. Researchers then relate that target to the affected function, such as autonomic regulation, cognition, glandular secretion, airway tone, heart rate, or skeletal muscle movement. This workflow links molecular action to pharmacological outcome.
It is relevant when investigators need to modify excessive cholinergic activity or deliberately alter a cholinergic pathway. Mechanistic distinctions guide the selection of antimuscarinic drugs, ganglionic blockers, neuromuscular blockers, or release-inhibiting agents such as botulinum toxin. Understanding the target supports evaluation of intended effects across autonomic, cognitive, and motor functions.
Assessment should connect the inhibitory mechanism with measurable changes in cholinergic functions. Depending on the target, relevant outcomes may include altered heart rate, airway tone, glandular secretion, cognition, autonomic regulation, or skeletal muscle movement. Reviewing these effects together helps determine whether the intervention primarily affects muscarinic signaling, nicotinic signaling, or acetylcholine release.